Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a 25% revenue increase and reduced net loss, which are positive indicators. However, the lack of discussion on strategic initiatives, operational updates, or shareholder returns limits the positive impact. The increase in R&D expenses and slight decrease in cash reserves are neutral factors, balancing the overall sentiment. The absence of Q&A insights further supports a neutral stance. Without additional context on market cap or strategic developments, the stock price is likely to remain stable, resulting in a neutral prediction.
Key Financial Performance
Revenue Madrigal Pharmaceuticals reported a revenue of $45 million for Q1 2026, which represents a 25% increase year-over-year. This growth was primarily driven by the successful launch of their new drug, Resmetirom, and increased market penetration.
Net Loss The company reported a net loss of $30 million for Q1 2026, compared to a net loss of $40 million in Q1 2025. This improvement was attributed to higher revenues and cost management initiatives.
Research and Development (R&D) Expenses R&D expenses were $20 million in Q1 2026, up 10% year-over-year. The increase was due to expanded clinical trials for Resmetirom and other pipeline programs.
General and Administrative (G&A) Expenses G&A expenses were $15 million in Q1 2026, a 5% increase year-over-year, driven by higher personnel costs and investments in infrastructure to support growth.
Cash and Cash Equivalents The company ended Q1 2026 with $200 million in cash and cash equivalents, down from $220 million at the end of Q1 2025. The decrease was primarily due to increased R&D spending and operational costs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Ashwani Verma
Bank Research
CFO Prakhar
Chief Investor
Co Research
Cowen Research
DiFiore Evercore
Director Soergel
Division Ashwani
Division DiFiore
Division EDT
Division Eliana
Division Jonathan
Division Ritu
Division Smith
Division Srikripa
Division Wood
Division Yasmeen
EDT Madrigal
Eliana Merle
Executive VP
Inc Research
Jonathan Wolleben
LLC Research
Mardi Dier
Merle Barclays
Officer Mardi
Piper Sandler
Rahimi Piper
Relations Officer
Research Division
Sandler Co
Securities Inc
MDGL Transcript
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2026 Earnings Call Transcript
Unknown5-6
The earnings call highlights a 25% revenue increase and reduced net loss, which are positive indicators. However, the lack of discussion on strategic initiatives, operational updates, or shareholder returns limits the positive impact. The increase in R&D expenses and slight decrease in cash reserves are neutral factors, balancing the overall sentiment. The absence of Q&A insights further supports a neutral stance. Without additional context on market cap or strategic developments, the stock price is likely to remain stable, resulting in a neutral prediction.
Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2025 Earnings Call Transcript
Positive2-19
The earnings call highlights strong financial performance, strategic product development, and optimistic market strategies. Despite some uncertainties in the European market, the company shows robust growth potential, especially in the U.S. The Q&A session indicates positive analyst sentiment and confidence in future growth. The strategic focus on expanding patient numbers and maintaining high adherence rates supports a positive outlook. However, the absence of specific guidance and European market uncertainties slightly temper the overall sentiment.
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
MDGL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
